Agreed, if all you are considering is efficacy.
But the high roll over into Lilac suggests that there were no issues with side effects or safety concerns by parents.
The FDA is more likely to approve a new drug, even with limited efficacy, if a) there are no other treatments and 2) there are no safety or tolerance issues.
ACADIA earnings, page-68
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.61 |
Change
0.400(2.63%) |
Mkt cap ! $1.994B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $4.383M | 280.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 1785 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.61 | 644 | 17 |
View Market Depth
| Last trade - 15.08pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |